MoonLake Immunotherapeutics [MLTX] stock prices are down -2.16% to $18.09 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The MLTX shares have gain 61.66% over the last week, with a monthly amount glided 23.82%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
MoonLake Immunotherapeutics [NASDAQ: MLTX] stock has seen the most recent analyst activity on January 09, 2026, when BTIG Research upgraded its rating to a Buy but kept the price target unchanged to $24 for it. Previously, H.C. Wainwright upgraded its rating to Buy on November 03, 2025, and kept the price target unchanged to $30. On October 02, 2025, downgrade downgraded it’s rating to Neutral. Goldman downgraded its rating to a Neutral but stick to its price target of $7 on October 01, 2025. Wolfe Research downgraded its rating to an Underperform but $2 remained the price target by the analyst firm on September 30, 2025. Citigroup downgraded its rating to Neutral for this stock on September 30, 2025, but kept the price target unchanged to $5. In a note dated September 29, 2025, Stifel downgraded a Hold rating on this stock but restated the target price of $13.
The stock price of MoonLake Immunotherapeutics [MLTX] has been fluctuating between $5.95 and $62.75 over the past year. Currently, Wall Street analysts expect the stock to reach $18.88 within the next 12 months. MoonLake Immunotherapeutics [NASDAQ: MLTX] shares were valued at $18.09 at the most recent close of the market. An investor can expect a potential return of 4.37% based on the average MLTX price forecast.
Analyzing the MLTX fundamentals
Gross Profit Margin for this corporation currently stands at -10.82% with Operating Profit Margin at -1972.27%, Pretax Profit Margin comes in at -1754.92%, and Net Profit Margin reading is -1732.62%. To continue investigating profitability, this company’s Return on Assets is posted at -0.38, Equity is -0.42 and Total Capital is -0.46. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.21.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that MoonLake Immunotherapeutics [NASDAQ:MLTX]’s Current Ratio is 8.50. In addition, the Quick Ratio stands at 8.50 and the Cash Ratio stands at 11.21.
Transactions by insiders
Recent insider trading involved Santos da Silva Jorge, Chief Executive Officer, that happened on Dec 08 ’25 when 0.13 million shares were sold. Chief Executive Officer, Santos da Silva Jorge completed a deal on Dec 09 ’25 to sell 70000.0 shares. Meanwhile, Chief Scientific Officer Reich Kristian sold 0.13 million shares on Dec 08 ’25.
